Inquiry Basket
Loading ......
Filter By Product Search for
APOA2
APOA2 Full Name
apolipoprotein A-II
APOA2 Introduction
For many researchers and clinicians working in metabolic disease, cardiovascular biology, or translational biomarker discovery, APOA2 (apolipoprotein A-II) has become increasingly difficult to ignore. As the second most abundant protein component of high-density lipoprotein (HDL), ApoA-II accounts for nearly 20% of HDL-associated proteins and plays a central role in lipid transport, lipoprotein remodeling, and systemic metabolic balance. Unlike ApoA-I, whose anti-atherogenic role is relatively well established, ApoA-II presents a far more complex and sometimes contradictory biological profile, making it an especially intriguing therapeutic and diagnostic target. Human ApoA-II exists primarily as a disulfide-linked homodimer, and its structural interaction with HDL particles can directly influence cholesterol handling, triglyceride metabolism, and HDL stability. Recent mechanistic studies further demonstrated that APOA2 can enhance cholesterol efflux capacity by displacing the C-terminal region of resident ApoA-I on HDL particles, highlighting its importance in reverse cholesterol transport and lipid homeostasis. These findings are particularly relevant for researchers attempting to address persistent cardiovascular risk in patients whose lipid abnormalities are not fully explained by traditional cholesterol markers.
The clinical significance of APOA2 extends well beyond classical lipid metabolism. Elevated ApoA-II levels have been associated with hypertriglyceridemia, insulin resistance, obesity, impaired glucose tolerance, and the progression of type 2 diabetes, suggesting that dysregulated APOA2 signaling may contribute to a harmful metabolic feedback loop. In patients with chronic metabolic inflammation, increased glucose levels may further stimulate APOA2 transcription, potentially worsening cardiometabolic dysfunction over time. At the same time, ApoA-II has shown disease-specific and species-dependent behavior, complicating the interpretation of preclinical studies and translational models. Some experimental systems suggest pro-atherogenic effects, while others demonstrate anti-inflammatory or anti-atherosclerotic properties, reflecting the highly context-dependent biology of HDL remodeling. Beyond metabolic disease, APOA2 has also emerged as a clinically relevant biomarker in cancer progression, amyloidosis, chronic liver disease, and systemic inflammatory disorders. Notably, recent clinical investigations in septic shock demonstrated that genetically determined low ApoA-II levels are causally associated with increased short-term mortality, reinforcing the growing view that ApoA-II may function as an important regulator of innate immune responses, cytokine production, and organ protection during severe systemic inflammation.
Interest in APOA2 has also expanded into neuroscience and neurodegenerative disease research, where lipid transport and neuroinflammation are increasingly recognized as key pathological drivers. Although APOA2 mRNA expression is rarely detected within central nervous system tissue itself, ApoA-II protein has been identified in cerebrospinal fluid, suggesting transport across the blood-brain barrier or via the choroid plexus. Emerging evidence indicates that ApoA-II may influence cholesterol efflux, HDL metabolism, and inflammatory signaling within the brain microenvironment, potentially affecting the progression of disorders such as Alzheimer's disease and Parkinson's disease. This connection is particularly important because impaired lipid handling and chronic neuroinflammation are now considered central contributors to neuronal degeneration and cognitive decline. For pharmaceutical developers and biomarker researchers, APOA2 therefore represents more than a conventional lipid-associated protein—it is increasingly viewed as a multifunctional regulator linking metabolism, immunity, cardiovascular health, and neurological integrity. As precision medicine strategies continue to evolve, APOA2 may become an important target for risk stratification, therapeutic intervention, and next-generation HDL-focused drug development.
Alternate Names for APOA2
APOA2; apolipoprotein A-II; apoAII; Apo-AII; ApoA-II; apolipoprotein A2;
Loading ......
